Mechelen, Belgium; 14 January 2008 – Galapagos NV (Euronext & LSE: GLPG) announced today that its service division BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company (NYSE:LLY) until end 2008. Under the terms of the agreement, BioFocus DPI will screen certain compounds as provided by Lilly against certain selected assays in quarterly screening regimes to identify active compounds and provide selectivity information to Lilly for Lilly’s nuclear hormone receptor research program. Total contract extension value for Galapagos is expected to exceed $1.2 million.
The agreement extension announced today builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target nuclear hormone receptors, a class of proteins that, when bound to specific sequences of DNA, serve as on-off switches for controlling the development and differentiation of skin, bone, and behavioral centers in the brain, as well as the continual regulation of reproductive tissues. With this agreement, Lilly secures continued access to BioFocus DPI’s screening and biology expertise to discover compounds which “hit” these nuclear hormone receptors.
The extension agreement announced today is unrelated to the major collaboration with Lilly in osteoporosis that Galapagos announced on 19 December 2007, in which Galapagos’ drug discovery division will be responsible for the development of novel osteoporosis drug candidates potentially through to phase IIa clinical Proof of Concept.
“We are pleased to progress our relationship with Lilly, also as a service provider in drug discovery,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “This extension further demonstrates the ability of BioFocus DPI to build upon its success with existing big pharma relationships.”
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 460 people and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.